FibroGen to Report Second Quarter 2024 Financial Results
FibroGen Inc (NASDAQ: FGEN) has announced it will release its second quarter 2024 financial results on Tuesday, August 6, after the market closes.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
FibroGen Inc (NASDAQ: FGEN) has announced it will release its second quarter 2024 financial results on Tuesday, August 6, after the market closes. The company will host a conference call at 5:00 PM Eastern Time on the same day to discuss its corporate and financial performance with the investment community.
Investors can access the call via the following methods:
- Toll-free: 1-877-300-8521
- International: 1-412-317-6026
- Webcast: Available on FibroGen's website
Details
News Market Reaction – FGEN
The recorded move for FGEN in the trading session of this news was -47.56%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, July 30, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce second quarter 2024 financial results on Tuesday, August 6 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.
Conference Call and Webcast
Toll-free: 1-877-300-8521
International investors: 1-412-317-6026
Webcast: Click here
To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call. A replay of the webcast will also be available for a limited time on the “Events and Presentation” page under the Investors section on the FibroGen website.
About FibroGen
FibroGen, Inc. is a biopharmaceutical company focused on accelerating the development of novel therapies at the frontiers of cancer biology. Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. Roxadustat is in clinical development for chemotherapy-induced anemia (CIA) and a Supplemental New Drug Application (sNDA) has been accepted for review by the China Health Authority. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46 is in development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of an associated CD46-targeted PET biomarker. In addition, FibroGen has expanded its research and development portfolio to include two immuno-oncology product candidates for the treatment of solid tumors. For more information, please visit www.fibrogen.com.
For Investor Inquiries:
David DeLucia, CFA
Vice President of Corporate FP&A / Investor Relations
InvestorRelations@fibrogen.com
For Media Inquiries:
Simon Miller
Vice President, Marketing and Corporate Communications
media@fibrogen.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.